Skip to main content
. 2019 Jun 24;11(6):880. doi: 10.3390/cancers11060880

Table 3.

Bruton’s tyrosine kinase (BTK) immunohistochemistry (IHC) ≥ 80% and intensity 3: treatment received and disease status.

Variables N = 15 %
OS
Uncensored 9 60.00
Censored 6 40.00
Rapid disease
Yes 3 20.00
No 12 80.00
Metastatic recurrence
Yes 5 33.00
No 4 26.66
Missing 6 40.00
Adj chemotherapy received
Fluoropyrimidenes (only) 3 20.00
Fluoropyrimidines plus oxaliplatin 6 40.00
Missing 6 40.00